Yanal Murad, PhD, D(abmm), Mlt(csmls)
About Yanal Murad, PhD, D(abmm), Mlt(csmls)
Yanal Murad, PhD, D(abmm), Mlt(csmls), serves as the Director of Research and Group Leader for Cancer Immunotherapy at Virogin Biotech in Vancouver, Canada. He has contributed to several significant studies in cancer immunotherapy and holds multiple professional certifications.
Work at Virogin Biotech
Yanal Murad has been employed at Virogin Biotech since 2019. He currently serves as the Director of Research, a position he has held since 2020. In addition, he has been a Group Leader in Cancer Immunotherapy for five years. His work is based in Vancouver, British Columbia, Canada, where he focuses on advancing research in cancer treatment through innovative biotechnological approaches.
Education and Expertise
Yanal Murad holds a PhD, which signifies his advanced knowledge and expertise in his field. He also possesses a D(abmm) certification, indicating proficiency in laboratory medicine. Additionally, he holds a Mlt(csmls) certification, further demonstrating his qualifications in medical laboratory technology. These credentials support his role in research and development within the biotechnology sector.
Research Contributions
Yanal Murad has co-authored several significant publications in the field of cancer immunotherapy. Notably, he contributed to a publication on HER2-expressing Oncolytic Herpes Simplex Virus, which explores novel therapeutic strategies. He also co-authored a study on VG161, which investigates its role in activating systemic antitumor immunity in pancreatic cancer models. Furthermore, he contributed to a clinical report on VG2025, a non-attenuated HSV-1 oncolytic virus, highlighting his involvement in cutting-edge research.